<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:30:17Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7325072" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7325072</identifier>
        <datestamp>2020-06-30</datestamp>
        <setSpec>trials</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Trials</journal-id>
              <journal-id journal-id-type="iso-abbrev">Trials</journal-id>
              <journal-title-group>
                <journal-title>Trials</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1745-6215</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7325072</article-id>
              <article-id pub-id-type="pmcid">PMC7325072</article-id>
              <article-id pub-id-type="pmc-uid">7325072</article-id>
              <article-id pub-id-type="pmid">32600389</article-id>
              <article-id pub-id-type="publisher-id">4540</article-id>
              <article-id pub-id-type="doi">10.1186/s13063-020-04540-7</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Folic acid supplementation in children with sickle cell disease: study protocol for a double-blind randomized cross-over trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williams</surname>
                    <given-names>Brock A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McCartney</surname>
                    <given-names>Heather</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Adams</surname>
                    <given-names>Erin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Devlin</surname>
                    <given-names>Angela M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Singer</surname>
                    <given-names>Joel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vercauteren</surname>
                    <given-names>Suzanne</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wu</surname>
                    <given-names>John K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1025-2194</contrib-id>
                  <name>
                    <surname>Karakochuk</surname>
                    <given-names>Crystal D.</given-names>
                  </name>
                  <address>
                    <email>crystal.karakochuk@ubc.ca</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution>Food, Nutrition, and Health, Faculty of Land and Food Systems, </institution><institution>The University of British Columbia, </institution></institution-wrap>2205 East Mall, Vancouver, British Columbia V6T 1Z4 Canada </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.414137.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0684 7788</institution-id><institution>BC Children’s Hospital Research Institute, </institution></institution-wrap>950 W 28th Avenue, Vancouver, British Columbia V5Z 4H4 Canada </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution>Department of Pediatrics, Faculty of Medicine, </institution><institution>The University of British Columbia, </institution></institution-wrap>4480 Oak Street, Vancouver, British Columbia V6H 3V4 Canada </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.414137.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0684 7788</institution-id><institution>Department of Pharmacy, </institution><institution>BC Children’s Hospital, </institution></institution-wrap>4480 Oak Street, Vancouver, British Columbia V6H 3V4 Canada </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution>School of Population and Public Health, </institution><institution>The University of British Columbia, </institution></institution-wrap>2206 East Mall, Vancouver, British Columbia V6T 1Z3 Canada </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.416553.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 8589 2327</institution-id><institution>The Centre for Health Evaluation and Outcome Science, </institution><institution>St. Paul’s Hospital, </institution></institution-wrap>588 – 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6 Canada </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.414137.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0684 7788</institution-id><institution>Department of Pathology and Laboratory Medicine, </institution><institution>BC Children’s Hospital, </institution></institution-wrap>4480 Oak Street, Vancouver, British Columbia V6H 3V4 Canada </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>29</day>
                <month>6</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>29</day>
                <month>6</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>21</volume>
              <elocation-id>593</elocation-id>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>5</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2020</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Sickle cell disease (SCD) is a genetic disorder which causes dysfunctional red blood cells (RBC) and is thought to increase requirements for folate, an essential B vitamin, due to increased RBC production and turnover in the disease. High-dose supplementation with 1–5 mg/d folic acid, synthetic folate, has been the standard recommendation for children with SCD. There is concern about whether children with SCD need such high doses of folic acid, following mandatory folic acid fortification of enriched grains in Canada, and advancements in medical therapies which extend the average lifespan of RBCs. In animal and human studies, high folic acid intakes (1 mg/d) have been associated with accelerated growth of some cancers, and the biological effects of circulating unmetabolized folic acid (UMFA), which can occur with doses of folic acid ≥ 0.2 mg/d, are not fully understood. The objective of this study is to determine efficacy of, and alterations in folate metabolism from high-dose folic acid in children with SCD during periods of folic acid supplementation versus no supplementation.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">In this double-blind randomized controlled cross-over trial, children with SCD (<italic>n</italic> = 36, aged 2–19 years) will be randomized to either receive 1 mg/d folic acid, the current standard of care, or a placebo for 12 weeks. After a 12-week washout period, treatments will be reversed. Total folate concentrations (serum and RBC), different folate forms (including UMFA), folate-related metabolites, and clinical outcomes will be measured at baseline and after treatment periods. The sum of the values measured in the two periods will be calculated for each subject and compared across the two sequence groups by means of a test for independent samples for the primary (RBC folate concentrations) and secondary (UMFA) outcomes. Dietary intake will be measured at the beginning of each study period.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par3">As the first rigorously designed clinical trial in children with SCD, this trial will inform and assess current clinical practice, with the ultimate goal of improving nutritional status of children with SCD.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par4"><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04011345">NCT04011345</ext-link>. Registered on July 8, 2019</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Sickle cell disease</kwd>
                <kwd>Pediatrics</kwd>
                <kwd>Nutrition</kwd>
                <kwd>Folic acid</kwd>
                <kwd>Micronutrient supplementation</kwd>
                <kwd>Randomized control trial</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id>
                      <institution>Canadian Institutes of Health Research</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>419565</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Karakochuk</surname>
                      <given-names>Crystal D.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005627</institution-id>
                      <institution>Thrasher Research Fund</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>14798</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Karakochuk</surname>
                      <given-names>Crystal D.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Administrative information</title>
              <p id="Par16">Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see <ext-link ext-link-type="uri" xlink:href="http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/">http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/</ext-link>).
<table-wrap id="Taba"><table frame="hsides" rules="groups"><thead><tr><th>Title {1}</th><th>Folic Acid Supplementation in Children with Sickle Cell Disease:<break/>Study Protocol for a Double-Blind Randomized Cross-Over Trial</th></tr></thead><tbody><tr><td>Trial registration {2a and 2b}.</td><td><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">Clinicaltrials.gov</ext-link>: NCT04011345</td></tr><tr><td>Protocol version {3}</td><td>Version 5; December 10, 2019.</td></tr><tr><td>Funding {4}</td><td><p>Canadian Institutes of Health Research (CIHR)</p><p>Thrasher Research Fund</p></td></tr><tr><td>Author details {5a}</td><td><p><sup>1</sup> Food, Nutrition, and Health, Faculty of Land and Food Systems, The University of British Columbia, 2205 East Mall, Vancouver, British Columbia, Canada, V6T 1Z4</p><p><sup>2</sup> BC Children’s Hospital Research Institute, 950 W 28th Avenue, Vancouver, British Columbia, Canada, V5Z 4H4</p><p><sup>3</sup> Department of Pediatrics, Faculty of Medicine, The University of British Columbia, 4480 Oak Street, Vancouver, British Columbia, Canada, V6H 3V4</p><p><sup>4</sup> Department of Pharmacy, BC Children’s Hospital, 4480 Oak Street, Vancouver, British Columbia, Canada, V6H 3V4</p><p><sup>5</sup> School of Population and Public Health, The University of British Columbia, 2206 East Mall, Vancouver, British Columbia, Canada, V6T 1Z3</p><p><sup>6</sup> The Centre for Health Evaluation and Outcome Science, St. Paul’s Hospital, 588 – 1081 Burrard Street, Vancouver, British Columbia, Canada, V6Z 1Y6</p><p><sup>7</sup>Department of Pathology and Laboratory Medicine, BC Children’s Hospital, 4480 Oak Street, Vancouver, British Columbia, Canada, V6H 3V4</p></td></tr><tr><td>Name and contact information for the trial sponsor {5b}</td><td><p>Canadian Institutes of Health Research (CIHR)</p><p>160 Elgin Street, 10th FloorOttawa ON K1A 0W9Canada</p><p>+1-613-941-2672</p></td></tr><tr><td>Role of sponsor {5c}</td><td>The study sponsor and funders have no role in the study design, collection, management, analysis and interpretation of data, writing of the report or publication decisions.</td></tr></tbody></table></table-wrap></p>
            </sec>
            <sec id="Sec2">
              <title>Introduction</title>
              <sec id="Sec3">
                <title>Background and rationale {6a}</title>
                <p id="Par17">Sickle cell disease (SCD) is a rare, inherited hemoglobinopathy that affects over 5000 Canadians, including 3000 children and youth [<xref ref-type="bibr" rid="CR1">1</xref>]. In SCD, variants in the β-globin gene produce an abnormal sickle-hemoglobin molecule (HbS), which forms a rigid sickle shape upon release of oxygen due to polymerization [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. While the severity of disease can vary among homozygous and heterozygous genotypes, hallmarks of the disease include hemolytic anemia, vaso-occlusion, stroke, ischemic tissue damage, organ failure, and severe pain in the back, extremities, thorax, abdomen, and central nervous system [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Chronic hemolytic anemia and increased red blood cell (RBC) production and turnover in SCD are thought to increase the requirements of folate, a water-soluble family of compounds that are essential for erythropoiesis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Naturally occurring folate is commonly found in foods such as leafy green vegetables, oranges, beans, and legumes [<xref ref-type="bibr" rid="CR9">9</xref>], while dietary supplements and folate-fortified foods commonly contain folic acid (FA), the synthetic oxidized version of folate, due to its stability and higher bioavailability [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
                <p id="Par18">The Canadian Haemoglobinopathy Association recommends supplementation of 1–5 mg per day (mg/d) of FA in individuals with SCD in Canada [<xref ref-type="bibr" rid="CR1">1</xref>], largely based on studies conducted between 1975 to 2001 that showed individuals with SCD had low blood serum or RBC folate concentrations [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. The lowest recommended dose of 1 mg/d FA, however, provides 6 times more folate than is recommended for healthy children aged 1–3 years [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
                <p id="Par19">The biological effects of FA are not fully understood. In order to be biologically active, FA is reduced to dihydrofolate by dihydrofolate reductase (DHFR). However, the capacity for DHFR to metabolize large amounts of FA may be limited [<xref ref-type="bibr" rid="CR15">15</xref>]. Recent studies suggest that the maximal capacity for this process is much lower than was previously thought, so even intakes of FA as low as 0.2 mg will leave an appreciable amount of unmetabolized folic acid (UMFA) to be taken up into circulation [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p>
                <p id="Par20">There is limited evidence that FA supplementation improves hematological or clinical outcomes in individuals with SCD [<xref ref-type="bibr" rid="CR7">7</xref>]. Effectiveness of FA supplementation was largely investigated in the 1970–1980s and presented inconclusive evidence [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. A 1983 trial among 117 Jamaican children with SCD aged 6 months to 4 years, the only trial eligible for inclusion in the Cochrane Review of FA supplementation in individuals with SCD, examined the effect of 5 mg/d FA versus a placebo [<xref ref-type="bibr" rid="CR21">21</xref>]. Although authors observed an increase in serum folate levels (concentrations below 11 nmol/L were evident in 15% (<italic>n</italic> = 6/39) of children in the placebo group versus none of the folic acid group, while concentrations above 40 nmol/L were evident in 81% (<italic>n</italic> = 33/41) of the folic acid group versus 15% in the placebo (<italic>n</italic> = 15/39) group) after 1 year in those treated with FA, no effect on hemoglobin, growth parameters, or other clinical events was observed [<xref ref-type="bibr" rid="CR21">21</xref>]. The quality of the evidence, however, was low due to the high risk of bias in random sequence generation and incomplete data, making it difficult to draw conclusions from this trial [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
                <p id="Par21">There is mounting concern about whether Canadian children with SCD require high doses of FA, especially given the mandatory FA fortification of refined grains, specifically white flour, enriched pasta, and enriched corn meal, in Canada since 1998. It is estimated that Canadian children consume, on average, 331 ± 123 μg (<italic>n</italic> = 2193; children aged 1–3 years) to 699 ± 225 μg (<italic>n</italic> = 2397; adolescent males aged 14–18 years) per day of dietary folate equivalents (from both naturally occurring folate and folic acid) [<xref ref-type="bibr" rid="CR22">22</xref>]. With intake levels of this magnitude, the majority of Canadian children are predicted to meet the recommended dietary allowance for folate from food sources alone. Furthermore, the Canadian Health Measures Survey in 2011 showed that less than 1% of Canadians (<italic>n</italic> = 5248, 6–79 years) had folate deficiency (RBC folate &lt; 305 nmol/L) and 40% had high RBC folate concentrations (&gt; 1360 nmol/L) [<xref ref-type="bibr" rid="CR23">23</xref>]. In Canadian children with SCD, a recent Canadian study (<italic>n</italic> = 87, age 2–17 years) reported that there was no evidence of serum folate deficiency among individuals supplemented with 1 mg/d FA [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
                <p id="Par22">Advancements in medical therapy, specifically the use of hydroxyurea, a medication which extends the average lifespan of RBCs from a mean of 4.1 ± 2.71 days to 21.3 ± 6.44 days through the promotion of fetal hemoglobin concentrations [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], may also decrease folate requirements because of reduced RBC turnover. A 2017 study of US children with SCD (<italic>n</italic> = 72), the majority (96%) of which were prescribed hydroxyurea, reported that discontinuation of 1 mg/d FA for ~ 80 days did not change RBC folate concentrations and mean RBC folate concentrations remained high (4 times higher than the suggested World Health Organization deficiency cutoff of 340 nmol/L [<xref ref-type="bibr" rid="CR16">16</xref>]) after the discontinuation [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
                <p id="Par23">There is growing concern that higher FA intakes may lead to adverse health outcomes, as intakes of 1 mg/d FA have been associated with acceleration of mammary tumors in rats [<xref ref-type="bibr" rid="CR28">28</xref>], and colorectal [<xref ref-type="bibr" rid="CR29">29</xref>] and prostate [<xref ref-type="bibr" rid="CR30">30</xref>] cancer in adults. There is also evidence that excess FA intakes may have adverse effects on metabolic health during development [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] suggesting young children undergoing periods of rapid growth and development are especially vulnerable. The association of adverse health outcomes with high FA intake remains controversial, but debate has limited some countries from adopting mandatory nationwide FA fortification programs due to these concerns [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
                <p id="Par24">As no well-designed randomized controlled trial of FA supplementation on children with SCD has been conducted to date, the aim of this study is to determine if high-dose FA supplementation is efficacious, safe, and warranted in children with SCD.</p>
              </sec>
              <sec id="Sec4">
                <title>Objectives {7}</title>
                <p id="Par25">The primary objective is to assess the efficacy of high-dose FA supplementation by measuring the effect of 12 weeks of 1 mg/d FA on RBC folate concentrations, serum folate concentrations, and clinical outcomes (occurrence of megaloblastic anemia and acute pain crises) in children with SCD, compared to placebo.</p>
                <p id="Par26">The secondary objective is to assess alterations in folate metabolism from high-dose FA supplementation by measuring the effect of 12 weeks of 1 mg/d FA on plasma UMFA concentrations, and folate-related metabolite concentrations (plasma <italic>S</italic>-adenosylmethionine, <italic>S</italic>-adenosylhomocysteine, total homocysteine, vitamin B<sub>12</sub>, and methylmalonic acid) in children with SCD, compared to placebo.</p>
                <p id="Par27">We hypothesize that (1) none of the children will present with folate deficiency (RBC folate &lt; 340 nmol/L) during the study period, (2) mean RBC folate concentrations will be similar following 12 weeks of FA or placebo supplementation, showing no benefit of FA supplementation, and (3) plasma UMFA concentrations will be higher following 12 weeks of FA supplementation compared to levels following the placebo supplementation.</p>
              </sec>
              <sec id="Sec5">
                <title>Trial design {8}</title>
                <p id="Par28">This is a double-blind randomized controlled cross-over trial consisting of a 12 ± 1-week intervention period (treatment of 1 mg/d FA or placebo), followed by a 12 ± 1-week wash-out period and a reversal of treatments. The 12-week duration of the intervention and washout periods is based on the estimation that steady-state conditions of RBCs in children with SCD receiving hydroxyurea is reached before 80 days [<xref ref-type="bibr" rid="CR27">27</xref>]. Approximately 60% of the children with SCD at BC Children’s Hospital are prescribed hydroxyurea [<xref ref-type="bibr" rid="CR34">34</xref>]. The 12-week washout period will minimize the risk of any carryover effect of the first treatment.</p>
                <p id="Par29">The distinguishing advantage of a cross-over trial from a conventional parallel-arm trial is that each child will serve as his/her own control, thus reducing the bias of confounding variables (e.g., age, sex, dietary intake) [<xref ref-type="bibr" rid="CR35">35</xref>]. This design will also allow us higher power (lower sample size requirement) to determine a statistically significant treatment effect [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
                <p id="Par30">A non-inferiority framework will be used to determine whether placebo is inferior or non-inferior to FA, the current standard, for the maintenance of red blood cell folate concentrations.</p>
              </sec>
            </sec>
            <sec id="Sec6">
              <title>Methods: participants, interventions, and outcomes</title>
              <sec id="Sec7">
                <title>Study setting {9}</title>
                <p id="Par31">This trial will occur at BC Children’s Hospital (Canada), an affiliate academic hospital of the University of British Columbia (Canada).</p>
              </sec>
              <sec id="Sec8">
                <title>Eligibility criteria {10}</title>
                <p id="Par32">Individuals will be eligible for participation if (1) they have a confirmed diagnosis of SCD, (2) they are aged 2–19 years and attend BC Children’s Hospital for medical care, and (3) they have received routine daily supplementation of FA for the prior 12 weeks.</p>
                <p id="Par33">Individuals will be excluded from participation if (1) they have received a blood transfusion in the previous 12 weeks, (2) they are allergic to any components of the supplements (cellulose, methylcellulose, magnesium stearate, and/or titanium dioxide), (3) they have presented with megaloblastic anemia in the previous 12 weeks, (4) they have current pulmonary, renal, and/or cardiac complications (severe or recurrent acute chest syndrome), (5) they routinely take medications known to interfere with B vitamin metabolism (chloramphenicol, methotrexate, metformin, sulfasalazine, phenobarbital, primidone, triamterene, barbiturates), (6) they are currently pregnant, planning to become pregnant in the next 9 months, or currently breastfeeding, (7) they have participated in a clinical research trial in the previous 30 days, (8) they have donated blood in the previous 30 days, or (9) they have an unstable medical condition or laboratory results.</p>
              </sec>
              <sec id="Sec9">
                <title>Who will take informed consent? {26a}</title>
                <p id="Par34">Eligible individuals and their parents/legal guardians will be approached by the study coordinator (BAW) with information regarding the study at the out-patient hematology clinic at BC Children’s Hospital. Written informed consent and child or adolescent assent, as applicable, will be obtained.</p>
              </sec>
              <sec id="Sec10">
                <title>Additional consent provisions for collection and use of participant data and biological specimens {26b}</title>
                <p id="Par35">Not applicable</p>
              </sec>
              <sec id="Sec11">
                <title>Interventions</title>
                <sec id="Sec12">
                  <title>Explanation for the choice of comparators {6b}</title>
                  <p id="Par36">In this trial design, each participant will receive the current standard of care, 1 mg/d FA, and a placebo comparator for 12 ± 1 weeks. As previous studies have illustrated children with SCD prescribed routine prophylactic FA (1 mg/d) continue to have mean red blood cell folate concentrations 4 times higher than deficiency cutoffs after discontinuation of FA supplementation [<xref ref-type="bibr" rid="CR27">27</xref>], a placebo comparator was chosen given that treatment (supplementation) may be unnecessary in children, and folate concentrations are speculated to be adequate regardless of treatment group.</p>
                </sec>
                <sec id="Sec13">
                  <title>Intervention description {11a}</title>
                  <p id="Par37">Supplements are packaged in bottles containing 100 opaque capsules. The tablets, bottles, and labels on the bottle are identical in appearance except for a sticker which identifies the treatment group (A or B). Supplements will be dispensed from the BC Children’s Hospital Pharmacy at the beginning of each intervention period. Supplements will contain 1 mg FA or placebo, to be taken daily in the morning with food, for the 12 ± 1-week intervention periods. Individuals who cannot swallow capsules may open the capsules and add the powdered supplement to food products.</p>
                  <p id="Par38">Supplements were manufactured by Natural Factors Nutritional Products Ltd. (Coquitlam, British Columbia, Canada), and a Notice of Authorization for the purposes of this clinical trial was obtained from the Natural and Non-Prescription Health Products Directorate of Health Canada on December 4, 2019.</p>
                </sec>
                <sec id="Sec14">
                  <title>Criteria for discontinuing or modifying allocated interventions {11b}</title>
                  <p id="Par39">Premature withdrawal from the study may occur due to use of other medications which are contraindicated (FA-containing supplements), poor compliance with study protocols, participant request, and/or serious adverse events. Participants who are planning a pregnancy, or who have a confirmed pregnancy, during the intervention period will be removed from the clinical trial and will to return to receiving FA supplementation, as prescribed by their physician, according to the current standard of care. All previously collected data prior to withdrawal will be retained for analysis.</p>
                </sec>
                <sec id="Sec15">
                  <title>Strategies to improve adherence to interventions {11c}</title>
                  <p id="Par40">Adherence to study interventions will be monitored by the lead research pharmacist (EA) using capsule counts after each 12 ± 1-week study period and corroborated by supplement diaries which document date, time, and supplement consumption with or without food. The supplement diary will serve as a daily reminder to enhance adherence throughout the intervention periods.</p>
                </sec>
                <sec id="Sec16">
                  <title>Relevant concomitant care permitted or prohibited during the trial {11d}</title>
                  <p id="Par41">Consumption of other supplements containing FA is contraindicated for the duration of the study period. All other non-FA containing medications or natural health products approved or prescribed by a physician will be allowed for the duration of the study period.</p>
                </sec>
                <sec id="Sec17">
                  <title>Provisions for post-trial care {30}</title>
                  <p id="Par42">There will be medical follow-up for study participants after adverse events until symptoms have resolved or returned to baseline.</p>
                </sec>
                <sec id="Sec18">
                  <title>Outcomes {12}</title>
                  <sec id="FPar1">
                    <title>Blood collection and processing</title>
                    <p id="Par43">A 3-h fasting venous blood sample will be collected at BC Children’s Hospital and processed by the BC Children’s Hospital BioBank at baseline and the start of each 12 ± 1-week time period for the duration of the study period (weeks 0,12, 24, and 36). A 3-h fast is needed to avoid the confounding influence of recent food or synthetic FA intakes on serum folate levels, which has been shown to have a peak response in serum at 80 min followed by subsequent declines in serum concentrations [<xref ref-type="bibr" rid="CR36">36</xref>], while still detecting the presence of UMFA, which has been shown to be detectable for up to 10 h in fasted FA supplement users [<xref ref-type="bibr" rid="CR37">37</xref>]. Caregivers and/or children will be advised not to take the supplement/placebo the day of the blood collection.</p>
                    <p id="Par44">A total of 10 mL of venous blood will be collected in a 6-mL EDTA tube and 4-mL serum tube (BD Diagnostics). For preparation of whole blood hemolysate, whole blood (0.3 mL) will be removed from the 6 mL EDTA tube and diluted 1/11 by adding 3.0 mL of a 1% ascorbic acid solution and subsequently incubated at 37 °C for 30 min. Diluted whole blood will be aliquoted into three labeled microtubes. The remaining volume of the 6 mL EDTA tube will then be centrifuged at 3000 rpm for 15 min at 4 °C, and plasma and buffy coat will be collected. Plasma will be aliquoted into five labeled microtubes, and buffy coat will be aliquoted into a single labeled microtube.</p>
                    <p id="Par45">The 4 mL serum tube will be left at room temperature for ~ 30 min (until clotted), centrifuged at 3000 rpm for 15 min at 4 °C, and serum will be collected. Serum will be aliquoted into three labeled microtubes.</p>
                    <p id="Par46">All aliquots will be stored at − 80 °C until further analysis.</p>
                  </sec>
                </sec>
                <sec id="Sec19">
                  <title>Outcome measures</title>
                  <sec id="FPar2">
                    <title>Primary objective: efficacy of high-dose FA supplementation</title>
                    <p id="Par47">The primary outcome of the first study objective is total RBC folate concentrations (nmol/L) measured at baseline and endline of the intervention periods (weeks 0, 12, 24, and 36). RBC folate indicates longer term folate status, e.g., previous 3–4 months in healthy red blood cells, whereas serum folate reflects recent status or dietary intake [<xref ref-type="bibr" rid="CR38">38</xref>]. Serum folate will therefore be measured as a secondary outcome at baseline and endline of the intervention periods (weeks 0, 12, 24, and 36). Serum and RBC total folate will be assessed using two methods, as globally recommended [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]: serum folate using a microbiological assay [<xref ref-type="bibr" rid="CR41">41</xref>] and RBC folate using liquid chromatography-mass spectrometry (LC-MS) [<xref ref-type="bibr" rid="CR42">42</xref>]. RBC folate forms (tetrahydrofolate (THF), 5-methyl-THF, 5-formyl-THF, and 5,10-methenyl-THF) will be measured using LC-MS [<xref ref-type="bibr" rid="CR42">42</xref>]. Total RBC folate concentrations will be determined by subtracting serum folate from whole blood folate with a correction for hematocrit.</p>
                    <p id="Par48">Secondary clinical outcomes, the occurrence of acute pain crises and megaloblastic anemia, will be measured at baseline and endline of the intervention periods (weeks 0, 12, 24, and 36). Complete blood counts (CBC) will be prospectively collected from clinical blood work completed in tandem with research blood work. CBCs will be determined using an automated hematology analyzer. Megaloblastic anemia will be defined as an increase in MCV &gt; 3 fL and a reticulocyte count &lt; 100 × 10<sup>9</sup>/L, and/or unexplained neutropenia (platelets &lt; 100 × 10<sup>9</sup>/L) and thrombocytopenia (neutrophils &lt; 1.5 × 10<sup>9</sup>/L).</p>
                    <p id="Par49">Acute pain crises occurrence (defined as sudden onset of throbbing and continuous pain which can occur in one area of the body such as the back, joints, or arms/legs, or can move throughout areas of the body) will be determined using participant self-report and will be quantified (number of events) and qualified (severity determined by self-management at home, management in Emergency Department of a hospital, or management during an in-patient admission to a hospital ward).</p>
                  </sec>
                  <sec id="FPar3">
                    <title>Secondary objective: alterations in folate metabolism from high-dose FA</title>
                    <p id="Par50">The primary outcome of the second study objective is plasma UMFA concentrations (nmol/L) measured at baseline and endline of the intervention periods (weeks 0, 12, 24, and 36). Plasma UMFA concentrations will be measured using LC-MS [<xref ref-type="bibr" rid="CR42">42</xref>], as UMFA is not incorporated into RBCs [<xref ref-type="bibr" rid="CR43">43</xref>]. The proportion of children with detectable UMFA &gt; 0.2 nmol/L, and the proportion (%) of UMFA that makes up plasma total folate will be determined.</p>
                    <p id="Par51">Secondary outcome measures of folate-related metabolites (<italic>S</italic>-adenosylmethionine, <italic>S</italic>-adenosylhomocysteine, and total homocysteine concentrations) [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] will be measured using LC-MS [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] at baseline and endline of the intervention periods (weeks 0, 12, 24, and 36).</p>
                    <p id="Par52">Other outcome measures will consist of B vitamin status (vitamins B<sub>12</sub> and B<sub>6</sub>) measured at baseline and endline of the intervention periods (weeks 0, 12, 24, and 36), and dietary folate intake measured at baseline of the intervention periods (weeks 0, 12, 24). For the determination of status of vitamin B<sub>12</sub>, plasma methylmalonic acid (MMA), a marker of vitamin B<sub>12</sub> status [<xref ref-type="bibr" rid="CR48">48</xref>], will be measured using LC-MS [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], and plasma vitamin B<sub>12</sub> will be measured using an immunoanalyzer. For the determination of status of vitamin B<sub>6</sub>, pyridoxal-5′-phosphate (nmol/L), a marker of vitamin B<sub>6</sub>, will be measured using HPLC [<xref ref-type="bibr" rid="CR51">51</xref>].</p>
                    <p id="Par53">Dietary folate intake in children will be estimated using three 24-h dietary recalls, with a 5-step multiple pass method [<xref ref-type="bibr" rid="CR52">52</xref>], completed at the start of each 12 ± 1-week study period. Food models will be used to increase the accuracy of food portion estimates. Total dietary folate equivalents (DFEs) will be calculated, which takes into account the differences in bioavailability of dietary folate and synthetic FA (1 DFE = 1 μg dietary folate or 0.6 μg FA added to food) [<xref ref-type="bibr" rid="CR53">53</xref>]. As the potential confounding bias of dietary FA intakes in children will be minimized due to the cross-over design of the trial (each child will serve as his/her own control), estimated dietary FA intakes are not planned to be included in any statistical analyses.</p>
                    <p id="Par54">Gene variants associated with folate metabolism will also be measured at baseline (week 0). Genomic DNA will be extracted from buffy coat. <italic>MTHFR</italic> (677 C&gt;T, <italic>rs</italic>1801133, and 1298 A&gt;C, <italic>rs</italic>1801131) and <italic>DHFR</italic> (<italic>rs</italic>1643649 and <italic>rs</italic>70991108) variants [<xref ref-type="bibr" rid="CR54">54</xref>], which are known to influence folate metabolism, will be detected using polymerase chain reaction (PCR) [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>].</p>
                  </sec>
                </sec>
              </sec>
              <sec id="Sec20">
                <title>Participant timeline {13</title>
                <sec id="Sec21">
                  <title>Sample size {14}</title>
                  <p id="Par55">Sample size was estimated using data from the recent Nguyen et al. [<xref ref-type="bibr" rid="CR27">27</xref>] study in the USA to estimate means and standard deviation for RBC folate from children with SCD who had 1 mg/d FA discontinued. This population is similar to our clinical population in terms of national FA fortification policies and clinical management. A non-inferiority approach was used to determine the sample size needed to assess the efficacy of 1 mg/d FA as compared to the placebo. Assuming a single group standard deviation in RBC folate of 150 ng/mL (340 nmol/L) observed post-FA discontinuation, a difference in means between groups of 30 ng/mL (68 nmol/L) [<xref ref-type="bibr" rid="CR27">27</xref>], power of 0.8, alpha of 0.05, and a non-inferiority margin of 100 ng/mL (227 nmol/L) determined based on clinical significance, 28 children (14 in each treatment order) are needed to confirm that the RBC folate concentrations are at most 100 ng/mL (227 nmol/L) lower during the placebo period than during the FA supplementation period.</p>
                  <p id="Par56">Sample size was rounded up to 36 children (18 in each treatment order) to account for attrition and to be powered to detect clinically meaningful differences in our secondary outcome (UMFA concentrations).</p>
                </sec>
              </sec>
              <sec id="Sec22">
                <title>Recruitment {15}</title>
                <p id="Par57">Potential participants will first be provided a brief introduction to the study via email communication and later approached in-person in an outpatient clinic setting at BC Children’s Hospital by the study coordinator (BAW). Informed consent and child/adolescent assent will be obtained in person.</p>
              </sec>
              <sec id="Sec23">
                <title>Assignment of interventions: allocation</title>
                <sec id="Sec24">
                  <title>Sequence generation {16a}</title>
                  <p id="Par58">An independent research assistant from Natural Factors Nutritional Products Ltd. (Coquitlam, British Columbia, Canada) assigned blinding codes (A or B) to the FA and placebo supplements. The allocation sequence to treatment A or B was determined by a statistician unassociated with the study, under the direction of a clinical trialist (JS), via computer-generated random numbers in SAS statistical software, stratified in blocks of four to ensure roughly equal distribution of treatment order allocations during the study duration.</p>
                </sec>
                <sec id="Sec25">
                  <title>Concealment mechanism {16b}</title>
                  <p id="Par59">The generated allocation sequence and blinding codes were transferred directly via encrypted email from the clinical trialist (JS) to the lead research pharmacist (EA) dispensing the treatments in order to maintain blinding of allocation.</p>
                </sec>
                <sec id="Sec26">
                  <title>Implementation {16c}</title>
                  <p id="Par60">The lead research pharmacist (EA) will assign participants to treatment order based on the allocation sequence following the enrolment of participants by the blinded study coordinator (BAW).</p>
                </sec>
              </sec>
              <sec id="Sec27">
                <title>Assignment of interventions: blinding</title>
                <sec id="Sec28">
                  <title>Who will be blinded {17a}</title>
                  <p id="Par61">Clinicians/care providers, study personnel, outcome assessors, data analysts, and participants will be blinded to the allocation sequence. The sequence allocation will be kept confidential by research pharmacy personnel until full data analysis has been completed.</p>
                </sec>
                <sec id="Sec29">
                  <title>Procedure for unblinding if needed {17b}</title>
                  <p id="Par62">In an emergency situation, in which the health and safety of a participant is at risk, breaking the code of the double-blinded study may be done at the request of a medical practitioner responsible for the medical management of a participant to (1) to reveal treatment assignment to inform further medical treatment, (2) to provide information about the nature and risks of the particular treatment the participant is or has received, or (3) for the Principal Investigator to advise about the nature and risks associated with a particular treatment. The research pharmacy may make the randomization assignment result available to the Principal Investigator (CDK), for communication to the requesting clinician, upon reasonable request.</p>
                </sec>
              </sec>
              <sec id="Sec30">
                <title>Data collection and management</title>
                <sec id="Sec31">
                  <title>Plans for assessment and collection of outcomes {18a}</title>
                  <p id="Par63">Data (baseline questionnaires, dietary assessment, clinical outcomes, and adherence) and biochemistry will be prospectively collected throughout the study period according to the participant timeline (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The baseline questionnaire will collect information on disease genotype, region of ancestry, age, current use of supplements and medications (specifically antibiotics, vitamin D, FA, other vitamins and minerals, and hydroxyurea), and history of pain crisis occurrence in the previous 12 weeks.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Participant timeline</p></caption><graphic xlink:href="13063_2020_4540_Fig1_HTML" id="MO1"/></fig></p>
                </sec>
                <sec id="Sec32">
                  <title>Plans to promote participant retention and complete follow-up {18b}</title>
                  <p id="Par64">The provision of incentives ($25 gift card/study visit × 4 study visits) are planned to promote retention of study participants. Study visits are also planned in conjunction with regular clinic appointments to limit the burden of participation and promote complete follow-up.</p>
                </sec>
                <sec id="Sec33">
                  <title>Data management {19}</title>
                  <p id="Par65">Study data will be collected and managed using REDCap electronic data capture tools hosted at BC Children’s Hospital Research Institute. Mandatory entry fields, range checks, and double entry in the database will contribute to the promotion of data quality. Quality audits of data will be conducted by research personnel once data collection is complete.</p>
                </sec>
                <sec id="Sec34">
                  <title>Confidentiality {27}</title>
                  <p id="Par66">Data with personal identifiers will be stored on an encrypted, password-protected computer in a secure server space with the BC Children’s Hospital Research Institute. A copy of the supplement prescription containing patient identifiers and subject ID, required for dispensing, will be stored under double-lock storage in the hospital research pharmacy. All other data will be de-linked to protect confidentiality. Hard copy data will be stored under double-lock storage for a minimum of 25 years after publication in accordance with Health Canada requirements. Computerized data will be password-protected and stored in the encrypted BC Children’s Hospital Research Institute-maintained RedCap electronic data capture program via hospital network server. Biological samples will be stored in a locked freezer in the Principal Investigator’s (CDK) laboratory at the University of British Columbia.</p>
                </sec>
              </sec>
              <sec id="Sec35">
                <title>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}</title>
                <p id="Par67">In the current trial, genomic DNA will be extracted from buffy coat collected at baseline for the detection of <italic>MTHFR</italic> (677 C&gt;T, <italic>rs</italic>1801133, and 1298 A&gt;C, <italic>rs</italic>1801131) and <italic>DHFR</italic> (<italic>rs</italic>1643649 and <italic>rs</italic>70991108) variants. No further genetic or molecular analysis is planned.</p>
              </sec>
              <sec id="Sec36">
                <title>Statistical methods</title>
                <sec id="Sec37">
                  <title>Statistical methods for primary and secondary outcomes {20a}</title>
                  <p id="Par68">Intention-to-treat analyses, in which participants will be retained in their original assigned groups, will be performed using Stata 16 (Stata Corp, Texas). Two-sided <italic>p</italic> values less than 0.05 will indicate statistical significance.</p>
                  <p id="Par69">First, we will confirm that the washout period was long enough to rule out a carryover effect by conducting a preliminary test: the sum of the values measured in the two periods (for RBC folate concentration) will be calculated for each subject and compared across the two sequence groups by means of a test for independent samples [<xref ref-type="bibr" rid="CR35">35</xref>]. The 95% CI of the difference in means between treatments will be compared to the non-inferiority margin. If it does not exceed the margin, then we will support the hypothesis that placebo is non-inferior to supplementation [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
                  <p id="Par70">We will repeat the aforementioned analyses for our secondary outcomes (UMFA concentrations). We will also consider plasma UMFA &gt; 0.2 nmol/L as “detectable” levels of UMFA (as reported in previous studies) [<xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR59">59</xref>] and will calculate the proportion of children with concentrations &gt; 0.2 nmol/L in each group. We will also measure and compare plasma UMFA as a proportion of total blood (% of total blood) across groups. Lastly, we will compare blood folate forms across the groups in proportions of total folate, reduced folate forms, 5-methyl-THF, and UMFA. The “total folate” group will represent the sum of THF, 5-methyl-THF, 5,10-methyl-THF, 5-formyl-THF, and UMFA. The “reduced folate” group will represent the sum of THF, 5-methyl-THF, 5,10-methenyl-THF, and 5-formyl-THF.</p>
                </sec>
                <sec id="Sec38">
                  <title>Interim analyses {21b}</title>
                  <p id="Par71">A full review of safety data (occurrence of megaloblastic anemia and acute pain crises, in comparison with baseline measures) will be completed by our independent Data Safety and Monitoring Board (DSMB) after a quarter of the participants (<italic>n</italic> = 9) have completed the first 12 ± 1-week treatment period to ensure the safety of the interventions. Primary outcome measures will not be analyzed at this time.</p>
                </sec>
                <sec id="Sec39">
                  <title>Methods for additional analyses (e.g., subgroup analyses) {20b}</title>
                  <p id="Par72">No subgroup or adjusted analyses are planned.</p>
                </sec>
                <sec id="Sec40">
                  <title>Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}</title>
                  <p id="Par73">An intention-to-treat protocol will be used for data analysis. Multiple imputation will be used to correct for missing data, as appropriate [<xref ref-type="bibr" rid="CR60">60</xref>].</p>
                </sec>
                <sec id="Sec41">
                  <title>Plans to give access to the full protocol, participant level-data, and statistical code {31c}</title>
                  <p id="Par74">The full study protocol is publicly available via C<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">linicalTrials.gov</ext-link>: NCT04011345. De-identified data and statistical code will be provided to researchers who provide a methodologically sound proposal, following receipt of a signed data access agreement.</p>
                </sec>
              </sec>
              <sec id="Sec42">
                <title>Oversight and monitoring</title>
                <sec id="Sec43">
                  <title>Composition of the coordinating center and trial steering committee {5d}</title>
                  <p id="Par75">A multi-disciplinary steering committee was established to guide the research trial from conception to completion. Membership includes the Primary Investigator (CDK), the SCD Clinic Hematologist (JKW), and the SCD Nurse Clinician (HM). The steering committee will also lead knowledge translation planning activities. The data management team will consist of the study coordinator (BAW) and Principal Investigator (CDK).</p>
                </sec>
                <sec id="Sec44">
                  <title>Composition of the data monitoring committee, its role and reporting structure {21a}</title>
                  <p id="Par76">An independent DSMB consisting of three independent clinicians that, collectively, have experience in the management of patients with hemoglobinopathies/blood disorders and in the conduct and monitoring of randomized clinical trials has been established.</p>
                  <p id="Par77">The purpose of the DSMB meetings is to review the conduct of the trial to date and assess safety of the study intervention. A full review of safety data (occurrence of megaloblastic anemia and acute pain crises, in comparison with baseline measures) will be completed after a quarter of the participants (<italic>n</italic> = 9) have completed the first 12 ± 1-week treatment period. This data will be supplied, in strict confidence, to the DSMB, together with any other analyses that the committee may request. This may include analyses of data from other comparable trials. In the light of this review, the DSMB will advise the TSC (<italic>Trial Steering Committee</italic>) if in its view the study should be discontinued due to safety concerns. As there is evidence that children with SCD maintain adequate RBC folate concentrations following discontinuation of prophylactic FA supplementation, it is expected that the study will continue until planned completion.</p>
                </sec>
                <sec id="Sec45">
                  <title>Adverse event reporting and harms {22}</title>
                  <p id="Par78">Independent safety monitoring for the duration of the study will be continuous, with all adverse outcomes being reported during each 12 ± 1-week time period, according to protocol, to our DSMB, research ethics board, and health regulator.</p>
                </sec>
                <sec id="Sec46">
                  <title>Frequency and plans for auditing trial conduct {23}</title>
                  <p id="Par79">Trial conduct will follow Good Clinical Practice (GCP) guidelines for the safe and effective undertaking of the clinic trial. The Trial Steering Committee will be in charge of auditing trial conduct, and reviewing trial processes and documents to ensure that research activities comply with the requirements of the protocol on an annual basis. It will review screening and consent documentation to ensure ethical trial conduct.</p>
                </sec>
                <sec id="Sec47">
                  <title>Plans for communicating important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25}</title>
                  <p id="Par80">Any modifications to the protocol which may impact on the conduct of the study and potential benefit of the patient or may affect patient safety, including changes of study objectives, study design, patient population, sample sizes, study procedures, or significant administrative aspects, will be communicated to participants, investigators, research ethics board, regulators, registries, and journals, as applicable.</p>
                </sec>
              </sec>
              <sec id="Sec48">
                <title>Dissemination plans {31a}</title>
                <p id="Par81">Trial results will be disseminated to healthcare professionals, the public, and other relevant groups via open-access peer-reviewed publications and through presentations of findings at both national and international conferences and symposia.</p>
              </sec>
              <sec id="Sec49">
                <title>Trial status</title>
                <p id="Par82">Recruitment began February 2, 2020, and is expected to run until February 1, 2021. The current protocol version (version 5) is dated December 10, 2019.</p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>BC</term>
                  <def>
                    <p id="Par5">British Columbia</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CIHR</term>
                  <def>
                    <p id="Par6">Canadian Institutes of Health Research</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DSMB</term>
                  <def>
                    <p id="Par7">Data and Safety Monitoring Board</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FA</term>
                  <def>
                    <p id="Par8">Folic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RBC</term>
                  <def>
                    <p id="Par9">Red blood cell</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SAM</term>
                  <def>
                    <p id="Par10"><italic>S</italic>-adenosylmethionine</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SAH</term>
                  <def>
                    <p id="Par11"><italic>S</italic>-adenosylhomocysteine</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SCD</term>
                  <def>
                    <p id="Par12">Sickle cell disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TSC</term>
                  <def>
                    <p id="Par13">Trial Steering Committee</p>
                  </def>
                </def-item>
                <def-item>
                  <term>UBC</term>
                  <def>
                    <p id="Par14">University of British Columbia</p>
                  </def>
                </def-item>
                <def-item>
                  <term>UMFA</term>
                  <def>
                    <p id="Par15">Unmetabolized folic acid</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher’s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We thank Natural Factors Nutritional Products Ltd. (Coquitlam, British Columbia, Canada) for the in-kind donation of the compounded and packaged FA and placebo study supplements.</p>
              <p>We are grateful for the expertise and commitment of our Data Safety and Monitoring Board Members, Dr. Nicholas Au, Dr. Amanda Li, and Dr. Douglas Morrison.</p>
              <sec id="FPar4">
                <title>Authors’ contributions {31b}</title>
                <p id="Par83">CDK, AMD, SV, and JKW were responsible for study conception. BAW, HM, EA, AMD, JS, SV, JKW, and CDK were all involved in the protocol design and development. BAW and CDK wrote the first draft of the manuscript. All authors read and approved the final manuscript.</p>
              </sec>
              <sec id="FPar5">
                <title>Competing interests {28}</title>
                <p id="Par84">The authors declare that they have no competing interests.</p>
              </sec>
              <sec id="FPar6">
                <title>Funding {4}</title>
                <p id="Par85">Funding support is provided by project grants from the Canadian Institutes of Health Research and the Thrasher Research Fund. BAW is supported by a CIHR Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award. AMD is supported by an Investigator Grant from BC Children’s Hospital Research Institute. CDK is supported by a Michael Smith Foundation for Health Research Scholar Award. Funding agencies have no role in the design of the study, collection, analysis, and interpretation of data, or in the writing of manuscripts.</p>
              </sec>
              <sec id="FPar7">
                <title>Availability of data and materials {29}</title>
                <p id="Par86">The de-identified datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
              </sec>
              <sec id="FPar8">
                <title>Consent for publication {32}</title>
                <p id="Par87">Not applicable</p>
              </sec>
              <sec id="FPar9">
                <title>Ethics approval and consent to participate {24}</title>
                <p id="Par88">Ethical approval was obtained from the University of British Columbia Clinical Research Ethics Board (H18-02981) on January 3, 2020. Written informed consent will be obtained from all participants. Child and adolescent assent will be obtained, as appropriate.</p>
              </sec>
            </ack>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>The Canadian Haemoglobinopathy Association</collab>
                  </person-group>
                  <source>Consensus statement on the care of patients with sickle cell disease in Canada</source>
                  <year>2015</year>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schnog</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Duits</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Muskiet</surname>
                      <given-names>FA</given-names>
                    </name>
                    <name>
                      <surname>Ten Cate</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Rojer</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Brandjes</surname>
                      <given-names>DP</given-names>
                    </name>
                  </person-group>
                  <article-title>Sickle cell disease; a general overview</article-title>
                  <source>Neth J Med</source>
                  <year>2004</year>
                  <volume>62</volume>
                  <issue>10</issue>
                  <fpage>364</fpage>
                  <lpage>374</lpage>
                  <?supplied-pmid 15683091?>
                  <pub-id pub-id-type="pmid">15683091</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rees</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>TN</given-names>
                    </name>
                    <name>
                      <surname>Gladwin</surname>
                      <given-names>MT</given-names>
                    </name>
                  </person-group>
                  <article-title>Sickle-cell disease</article-title>
                  <source>Lancet.</source>
                  <year>2010</year>
                  <volume>376</volume>
                  <issue>9757</issue>
                  <fpage>2018</fpage>
                  <lpage>2031</lpage>
                  <?supplied-pmid 21131035?>
                  <pub-id pub-id-type="pmid">21131035</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kohne</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Hemoglobinopathies: clinical manifestations, diagnosis, and treatment</article-title>
                  <source>Dtsch Arztebl Int</source>
                  <year>2011</year>
                  <volume>108</volume>
                  <issue>31–32</issue>
                  <fpage>532</fpage>
                  <?supplied-pmid 3163784?>
                  <pub-id pub-id-type="pmid">21886666</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Piel</surname>
                      <given-names>FB</given-names>
                    </name>
                    <name>
                      <surname>Steinberg</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Rees</surname>
                      <given-names>DC</given-names>
                    </name>
                  </person-group>
                  <article-title>Sickle cell disease</article-title>
                  <source>N Engl J Med</source>
                  <year>2017</year>
                  <volume>376</volume>
                  <issue>16</issue>
                  <fpage>1561</fpage>
                  <lpage>1573</lpage>
                  <?supplied-pmid 28423290?>
                  <pub-id pub-id-type="pmid">28423290</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Al-Saqladi</surname>
                      <given-names>A-W</given-names>
                    </name>
                    <name>
                      <surname>Cipolotti</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Fijnvandraat</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Brabin</surname>
                      <given-names>BJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Growth and nutritional status of children with homozygous sickle cell disease</article-title>
                  <source>Ann Trop Paediatr</source>
                  <year>2008</year>
                  <volume>28</volume>
                  <issue>3</issue>
                  <fpage>165</fpage>
                  <lpage>189</lpage>
                  <?supplied-pmid 18727846?>
                  <pub-id pub-id-type="pmid">18727846</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <mixed-citation publication-type="other">Dixit R, Nettem S, Madan SS, Soe HHK, Abas ABL, Vance LD, et al. Folate supplementation in people with sickle cell disease. Cochrane Database Syst Rev. 2018;(3):CD011130.</mixed-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koury</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Ponka</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>New insights into erythropoiesis: the roles of folate, Vitamin B 12 , and iron</article-title>
                  <source>Annu Rev Nutr</source>
                  <year>2004</year>
                  <volume>24</volume>
                  <issue>1</issue>
                  <fpage>105</fpage>
                  <lpage>131</lpage>
                  <?supplied-pmid 15189115?>
                  <pub-id pub-id-type="pmid">15189115</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chan</surname>
                      <given-names>Y-M</given-names>
                    </name>
                    <name>
                      <surname>Bailey</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>O’Connor</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Folate</article-title>
                  <source>Adv Nutr</source>
                  <year>2013</year>
                  <volume>4</volume>
                  <issue>1</issue>
                  <fpage>123</fpage>
                  <lpage>125</lpage>
                  <?supplied-pmid 23319130?>
                  <pub-id pub-id-type="pmid">23319130</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lamers</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>MacFarlane</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>O’Connor</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Fontaine-Bisson</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Periconceptional intake of folic acid among low-risk women in Canada: summary of a workshop aiming to align prenatal folic acid supplement composition with current expert guidelines</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2018</year>
                  <volume>108</volume>
                  <issue>6</issue>
                  <fpage>1357</fpage>
                  <lpage>1368</lpage>
                  <?supplied-pmid 30541097?>
                  <pub-id pub-id-type="pmid">30541097</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Der Dijs</surname>
                      <given-names>FB</given-names>
                    </name>
                    <name>
                      <surname>Schnog</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Brouwer</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Velvis</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Van Den Berg</surname>
                      <given-names>GA</given-names>
                    </name>
                    <name>
                      <surname>Bakker</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients</article-title>
                  <source>Am J Hematol</source>
                  <year>1998</year>
                  <volume>59</volume>
                  <issue>3</issue>
                  <fpage>192</fpage>
                  <lpage>198</lpage>
                  <?supplied-pmid 9798656?>
                  <pub-id pub-id-type="pmid">9798656</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kennedy</surname>
                      <given-names>TS</given-names>
                    </name>
                    <name>
                      <surname>Fung</surname>
                      <given-names>EB</given-names>
                    </name>
                    <name>
                      <surname>Kawchak</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Zemel</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Ohene-Frempong</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Stallings</surname>
                      <given-names>VA</given-names>
                    </name>
                  </person-group>
                  <article-title>Red blood cell folate and serum vitamin B12 status in children with sickle cell disease</article-title>
                  <source>J Pediatr Hematol Oncol</source>
                  <year>2001</year>
                  <volume>23</volume>
                  <issue>3</issue>
                  <fpage>165</fpage>
                  <lpage>169</lpage>
                  <?supplied-pmid 11305720?>
                  <pub-id pub-id-type="pmid">11305720</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>YK</given-names>
                    </name>
                  </person-group>
                  <article-title>Folic acid deficiency in sickle cell anaemia</article-title>
                  <source>Scand J Haematol</source>
                  <year>1975</year>
                  <volume>14</volume>
                  <issue>1</issue>
                  <fpage>71</fpage>
                  <lpage>79</lpage>
                  <?supplied-pmid 1121649?>
                  <pub-id pub-id-type="pmid">1121649</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Otten</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Hellwig</surname>
                      <given-names>JPML</given-names>
                    </name>
                  </person-group>
                  <source>Dietary reference intakes: the essential guide to nutrient requirements</source>
                  <year>2006</year>
                  <publisher-loc>Washington D.C.</publisher-loc>
                  <publisher-name>National Academies Press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patanwala</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>King</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Barrett</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Rose</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Jackson</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hudson</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Folic acid handling by the human gut: implications for food fortification and supplementation</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2014</year>
                  <volume>100</volume>
                  <issue>2</issue>
                  <fpage>593</fpage>
                  <lpage>599</lpage>
                  <?supplied-pmid 24944062?>
                  <pub-id pub-id-type="pmid">24944062</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kelly</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>McPartlin</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Goggins</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Weir</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>1997</year>
                  <volume>65</volume>
                  <issue>6</issue>
                  <fpage>1790</fpage>
                  <lpage>1795</lpage>
                  <?supplied-pmid 9174474?>
                  <pub-id pub-id-type="pmid">9174474</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lindenbaum</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Klipstein</surname>
                      <given-names>FA</given-names>
                    </name>
                  </person-group>
                  <article-title>Folic acid deficiency in sickle-cell anemia</article-title>
                  <source>N Engl J Med</source>
                  <year>1963</year>
                  <volume>269</volume>
                  <issue>17</issue>
                  <fpage>875</fpage>
                  <lpage>882</lpage>
                  <?supplied-pmid 14050985?>
                  <pub-id pub-id-type="pmid">14050985</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hendrickse</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Barnes</surname>
                      <given-names>PM</given-names>
                    </name>
                  </person-group>
                  <article-title>Sickle cell anaemia: report of a therapeutic trial</article-title>
                  <source>West Afr Med J</source>
                  <year>1966</year>
                  <volume>15</volume>
                  <issue>2</issue>
                  <fpage>55</fpage>
                  <lpage>64</lpage>
                  <?supplied-pmid 5326524?>
                  <pub-id pub-id-type="pmid">5326524</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alperin</surname>
                      <given-names>JB</given-names>
                    </name>
                  </person-group>
                  <article-title>Folic acid deficiency complicating sickle cell anemia: a study on the response to titrated doses of folic acid</article-title>
                  <source>Arch Intern Med</source>
                  <year>1967</year>
                  <volume>120</volume>
                  <issue>3</issue>
                  <fpage>298</fpage>
                  <lpage>306</lpage>
                  <?supplied-pmid 6038289?>
                  <pub-id pub-id-type="pmid">6038289</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Watson-Williams</surname>
                      <given-names>EJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Folic acid deficiency in sickle-cell anaemia</article-title>
                  <source>East Afr Med J</source>
                  <year>1962</year>
                  <volume>39</volume>
                  <fpage>213</fpage>
                  <lpage>221</lpage>
                  <?supplied-pmid 14005324?>
                  <pub-id pub-id-type="pmid">14005324</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rabb</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Grandison</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Mason</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hayes</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Serjeant</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Serjeant</surname>
                      <given-names>GR</given-names>
                    </name>
                  </person-group>
                  <article-title>A trial of folate supplementation in children with homozygous sickle cell disease</article-title>
                  <source>Br J Haematol</source>
                  <year>1983</year>
                  <volume>54</volume>
                  <issue>4</issue>
                  <fpage>589</fpage>
                  <lpage>594</lpage>
                  <?supplied-pmid 6347243?>
                  <pub-id pub-id-type="pmid">6347243</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shakur</surname>
                      <given-names>YA</given-names>
                    </name>
                    <name>
                      <surname>Garriguet</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Corey</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>O’Connor</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Folic acid fortification above mandated levels results in a low prevalence of folate inadequacy among Canadians</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2010</year>
                  <volume>92</volume>
                  <issue>4</issue>
                  <fpage>818</fpage>
                  <lpage>825</lpage>
                  <?supplied-pmid 20739423?>
                  <pub-id pub-id-type="pmid">20739423</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Colapinto</surname>
                      <given-names>CK</given-names>
                    </name>
                    <name>
                      <surname>O’Connor</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Tremblay</surname>
                      <given-names>MS</given-names>
                    </name>
                  </person-group>
                  <article-title>Folate status of the population in the Canadian Health Measures Survey</article-title>
                  <source>CMAJ.</source>
                  <year>2011</year>
                  <volume>183</volume>
                  <issue>2</issue>
                  <fpage>E100</fpage>
                  <lpage>E106</lpage>
                  <?supplied-pmid 21149516?>
                  <pub-id pub-id-type="pmid">21149516</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Martyres</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Vijenthira</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Barrowman</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Harris-Janz</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chretien</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Klaassen</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Nutrient insufficiencies/deficiencies in children with sickle cell disease and its association with increased disease severity</article-title>
                  <source>Pediatr Blood Cancer</source>
                  <year>2016</year>
                  <volume>63</volume>
                  <issue>6</issue>
                  <fpage>1060</fpage>
                  <lpage>1064</lpage>
                  <?supplied-pmid 26855061?>
                  <pub-id pub-id-type="pmid">26855061</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ballas</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Marcolina</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Dover</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Barton</surname>
                      <given-names>FB</given-names>
                    </name>
                  </person-group>
                  <article-title>Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea</article-title>
                  <source>Br J Haematol</source>
                  <year>1999</year>
                  <volume>105</volume>
                  <issue>1995</issue>
                  <fpage>491</fpage>
                  <lpage>496</lpage>
                  <?supplied-pmid 10233426?>
                  <pub-id pub-id-type="pmid">10233426</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Steinberg</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Chui</surname>
                      <given-names>DHK</given-names>
                    </name>
                    <name>
                      <surname>Dover</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Sebastiani</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Alsultan</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Fetal hemoglobin in sickle cell anemia: a glass half full?</article-title>
                  <source>Blood.</source>
                  <year>2014</year>
                  <volume>123</volume>
                  <issue>4</issue>
                  <fpage>481</fpage>
                  <lpage>485</lpage>
                  <?supplied-pmid 24222332?>
                  <pub-id pub-id-type="pmid">24222332</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nguyen</surname>
                      <given-names>GKT</given-names>
                    </name>
                    <name>
                      <surname>Lewis</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Goldener</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Reed</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Dulman</surname>
                      <given-names>RY</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Discontinuation of folic acid supplementation in young patients with sickle cell anemia</article-title>
                  <source>J Pediatr Hematol Oncol</source>
                  <year>2017</year>
                  <volume>39</volume>
                  <issue>6</issue>
                  <fpage>470</fpage>
                  <lpage>472</lpage>
                  <?supplied-pmid 27571128?>
                  <pub-id pub-id-type="pmid">27571128</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Manshadi</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Ishiguro</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Sohn</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Medline</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Renlund</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Croxford</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Folic acid supplementation promotes mammary tumor progression in a rat model</article-title>
                  <source>PLoS One</source>
                  <year>2014</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <fpage>e84635</fpage>
                  <pub-id pub-id-type="pmid">24465421</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cole</surname>
                      <given-names>BF</given-names>
                    </name>
                    <name>
                      <surname>Baron</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Sandler</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Haile</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Ahnen</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Bresalier</surname>
                      <given-names>RS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Folic acid for the prevention of colorectal adenomas: a randomized clinical trial</article-title>
                  <source>JAMA.</source>
                  <year>2007</year>
                  <volume>297</volume>
                  <issue>21</issue>
                  <fpage>2351</fpage>
                  <lpage>2359</lpage>
                  <?supplied-pmid 17551129?>
                  <pub-id pub-id-type="pmid">17551129</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Figueiredo</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Grau</surname>
                      <given-names>MV</given-names>
                    </name>
                    <name>
                      <surname>Haile</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Sandler</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Summers</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Bresalier</surname>
                      <given-names>RS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Folic acid and risk of prostate cancer: results from a randomized clinical trial</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2009</year>
                  <volume>101</volume>
                  <issue>6</issue>
                  <fpage>432</fpage>
                  <lpage>435</lpage>
                  <?supplied-pmid 19276452?>
                  <pub-id pub-id-type="pmid">19276452</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Henderson</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Tai</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Aleliunas</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Aljaadi</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Glier</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>EE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Maternal folic acid supplementation with vitamin B12 deficiency during pregnancy and lactation affects the metabolic health of adult female offspring but is dependent on offspring diet</article-title>
                  <source>FASEB J</source>
                  <year>2018</year>
                  <volume>32</volume>
                  <issue>9</issue>
                  <fpage>5039</fpage>
                  <lpage>5050</lpage>
                  <?supplied-pmid 29913560?>
                  <pub-id pub-id-type="pmid">29913560</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yajnik</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Deshpande</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Jackson</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Refsum</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Rao</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Fisher</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study</article-title>
                  <source>Diabetologia.</source>
                  <year>2008</year>
                  <volume>51</volume>
                  <issue>1</issue>
                  <fpage>29</fpage>
                  <lpage>38</lpage>
                  <?supplied-pmid 17851649?>
                  <pub-id pub-id-type="pmid">17851649</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vollset</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Clarke</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lewington</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ebbing</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Halsey</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lonn</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals</article-title>
                  <source>Lancet.</source>
                  <year>2013</year>
                  <volume>381</volume>
                  <issue>9871</issue>
                  <fpage>1029</fpage>
                  <lpage>1036</lpage>
                  <?supplied-pmid 23352552?>
                  <pub-id pub-id-type="pmid">23352552</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Samson</surname>
                      <given-names>KLI</given-names>
                    </name>
                    <name>
                      <surname>Mccartney</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Vercauteren</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Karakochuk</surname>
                      <given-names>CD</given-names>
                    </name>
                  </person-group>
                  <article-title>Prevalence of vitamin D deficiency varies widely by season in Canadian children and adolescents with sickle cell disease</article-title>
                  <source>J Clin Med</source>
                  <year>2018</year>
                  <volume>7</volume>
                  <issue>2</issue>
                  <fpage>E14</fpage>
                  <?supplied-pmid 29385701?>
                  <pub-id pub-id-type="pmid">29385701</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wellek</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Blettner</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>On the proper use of the crossover design in clinical trials</article-title>
                  <source>Dtsch Arztebl Int</source>
                  <year>2012</year>
                  <volume>109</volume>
                  <issue>15</issue>
                  <fpage>276</fpage>
                  <lpage>281</lpage>
                  <?supplied-pmid 22567063?>
                  <pub-id pub-id-type="pmid">22567063</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kelly</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>McPartlin</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>A combined high-performance liquid chromatographic–microbiological assay for serum folic acid</article-title>
                  <source>Anal Biochem</source>
                  <year>1996</year>
                  <volume>238</volume>
                  <issue>2</issue>
                  <fpage>179</fpage>
                  <lpage>183</lpage>
                  <?supplied-pmid 8660608?>
                  <pub-id pub-id-type="pmid">8660608</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bailey</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Mills</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Yetley</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Gahche</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Pfeiffer</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Dwyer</surname>
                      <given-names>JT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged ≥60 y in the United States</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2010</year>
                  <volume>92</volume>
                  <issue>2</issue>
                  <fpage>383</fpage>
                  <lpage>389</lpage>
                  <?supplied-pmid 20573790?>
                  <pub-id pub-id-type="pmid">20573790</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>WHO</collab>
                  </person-group>
                  <source>Serum and red blood cell folate concentrations for assessing folate status in populations</source>
                  <year>2015</year>
                  <publisher-loc>Geneva</publisher-loc>
                  <publisher-name>World Health Organization</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pfeiffer</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Sternberg</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Fazili</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Lacher</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>CL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Folate status and concentrations of serum folate forms in the US population: National Health and Nutrition Examination Survey 2011-2</article-title>
                  <source>Br J Nutr</source>
                  <year>2015</year>
                  <volume>113</volume>
                  <fpage>1965</fpage>
                  <lpage>1977</lpage>
                  <?supplied-pmid 25917925?>
                  <pub-id pub-id-type="pmid">25917925</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yetley</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Pfeiffer</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Phinney</surname>
                      <given-names>KW</given-names>
                    </name>
                    <name>
                      <surname>Fazili</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Lacher</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Bailey</surname>
                      <given-names>RL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Biomarkers of folate status in NHANES: a roundtable summary</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2011</year>
                  <volume>94</volume>
                  <issue>1</issue>
                  <fpage>303S</fpage>
                  <lpage>312S</lpage>
                  <?supplied-pmid 21593502?>
                  <pub-id pub-id-type="pmid">21593502</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Molloy</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method</article-title>
                  <source>Methods Enzymol</source>
                  <year>1997</year>
                  <volume>281</volume>
                  <fpage>43</fpage>
                  <lpage>53</lpage>
                  <?supplied-pmid 9250965?>
                  <pub-id pub-id-type="pmid">9250965</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pfeiffer</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Fazili</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>McCoy</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gunter</surname>
                      <given-names>EW</given-names>
                    </name>
                  </person-group>
                  <article-title>Determination of folate vitamers in human serum by stable-isotope-dilution tandem mass spectrometry and comparison with radioassay and microbiologic assay</article-title>
                  <source>Clin Chem</source>
                  <year>2004</year>
                  <volume>50</volume>
                  <issue>2</issue>
                  <fpage>423</fpage>
                  <lpage>432</lpage>
                  <?supplied-pmid 14670827?>
                  <pub-id pub-id-type="pmid">14670827</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Sahyoun</surname>
                      <given-names>NR</given-names>
                    </name>
                  </person-group>
                  <article-title>Application of the key events dose-response framework to folate metabolism</article-title>
                  <source>Crit Rev Food Sci Nutr</source>
                  <year>2016</year>
                  <volume>56</volume>
                  <issue>8</issue>
                  <fpage>1325</fpage>
                  <lpage>1333</lpage>
                  <?supplied-pmid 25674817?>
                  <pub-id pub-id-type="pmid">25674817</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Clarke</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Banfield</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Carmel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Jacobsen</surname>
                      <given-names>DW</given-names>
                    </name>
                  </person-group>
                  <article-title>S-adenosylmethionine-dependent methyltransferases</article-title>
                  <source>Homocysteine in health and disease</source>
                  <year>2001</year>
                  <publisher-loc>Cambridge</publisher-loc>
                  <publisher-name>Cambridge Press</publisher-name>
                  <fpage>3</fpage>
                  <lpage>78</lpage>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herbig</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Chiang</surname>
                      <given-names>EP</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>LR</given-names>
                    </name>
                    <name>
                      <surname>Hills</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Shane</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Stover</surname>
                      <given-names>PJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses</article-title>
                  <source>J Biol Chem</source>
                  <year>2002</year>
                  <volume>277</volume>
                  <issue>41</issue>
                  <fpage>38381</fpage>
                  <lpage>38389</lpage>
                  <?supplied-pmid 12161434?>
                  <pub-id pub-id-type="pmid">12161434</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Finkelstein</surname>
                      <given-names>JD</given-names>
                    </name>
                  </person-group>
                  <article-title>The metabolism of homocysteine: pathways and regulation</article-title>
                  <source>Eur J Pediatr</source>
                  <year>1998</year>
                  <volume>157</volume>
                  <fpage>S40</fpage>
                  <lpage>S44</lpage>
                  <?supplied-pmid 9587024?>
                  <pub-id pub-id-type="pmid">9587024</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arning</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bottiglieri</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantitation of S-adenosylmethionine and S-adenosylhomocysteine in plasma using liquid chromatography-electrospray tandem mass spectrometry</article-title>
                  <source>Methods in molecular biology</source>
                  <year>2016</year>
                  <fpage>255</fpage>
                  <lpage>262</lpage>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carmel</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2011</year>
                  <volume>94</volume>
                  <issue>1</issue>
                  <fpage>348S</fpage>
                  <lpage>358S</lpage>
                  <?supplied-pmid 21593511?>
                  <pub-id pub-id-type="pmid">21593511</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McNulty</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Intake and status of folate and related B-vitamins: considerations and challenges in achieving optimal status</article-title>
                  <source>Br J Nutr</source>
                  <year>2008</year>
                  <volume>99</volume>
                  <issue>Suppl 3</issue>
                  <fpage>S48</fpage>
                  <lpage>S54</lpage>
                  <?supplied-pmid 18598588?>
                  <pub-id pub-id-type="pmid">18598588</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schroder</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Quay</surname>
                      <given-names>TAW</given-names>
                    </name>
                    <name>
                      <surname>Lamers</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Methylmalonic acid quantified in dried blood spots provides a precise, valid, and stable measure of functional vitamin B12 status in healthy women</article-title>
                  <source>J Nutr</source>
                  <year>2014</year>
                  <volume>144</volume>
                  <fpage>1658</fpage>
                  <lpage>1663</lpage>
                  <?supplied-pmid 25143369?>
                  <pub-id pub-id-type="pmid">25143369</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ubbink</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Serfontein</surname>
                      <given-names>WJ</given-names>
                    </name>
                    <name>
                      <surname>De Villiers</surname>
                      <given-names>LS</given-names>
                    </name>
                  </person-group>
                  <article-title>Stability of pyridoxal-5-phosphate semicarbazone: applications in plasma vitamin B6 analysis and population surveys of vitamin B6 nutritional status</article-title>
                  <source>J Chromatogr B Biomed Sci Appl</source>
                  <year>1985</year>
                  <volume>342</volume>
                  <fpage>277</fpage>
                  <lpage>284</lpage>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blanton</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Moshfegh</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Baer</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Kretsch</surname>
                      <given-names>MJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The USDA Automated Multiple-Pass Method accurately estimates group total energy and nutrient intake</article-title>
                  <source>J Nutr</source>
                  <year>2006</year>
                  <volume>136</volume>
                  <issue>10</issue>
                  <fpage>2594</fpage>
                  <lpage>2599</lpage>
                  <?supplied-pmid 16988132?>
                  <pub-id pub-id-type="pmid">16988132</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Suitor</surname>
                      <given-names>CW</given-names>
                    </name>
                    <name>
                      <surname>Bailey</surname>
                      <given-names>LB</given-names>
                    </name>
                  </person-group>
                  <article-title>Dietary folate equivalents: interpretation and application</article-title>
                  <source>J Am Diet Assoc</source>
                  <year>2000</year>
                  <volume>100</volume>
                  <issue>1</issue>
                  <fpage>88</fpage>
                  <lpage>94</lpage>
                  <?supplied-pmid 10646010?>
                  <pub-id pub-id-type="pmid">10646010</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalmbach</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Choumenkovitch</surname>
                      <given-names>SF</given-names>
                    </name>
                    <name>
                      <surname>Troen</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>D’Agostino</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Jacques</surname>
                      <given-names>PF</given-names>
                    </name>
                    <name>
                      <surname>Selhub</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Circulating folic acid in plasma: relation to folic acid fortification</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2008</year>
                  <volume>88</volume>
                  <issue>3</issue>
                  <fpage>763</fpage>
                  <lpage>768</lpage>
                  <?supplied-pmid 18779294?>
                  <pub-id pub-id-type="pmid">18779294</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frosst</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Blom</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <name>
                      <surname>Milos</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Goyette</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sheppard</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Matthews</surname>
                      <given-names>RG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase</article-title>
                  <source>Nature.</source>
                  <year>1995</year>
                  <volume>10</volume>
                  <fpage>111</fpage>
                  <lpage>113</lpage>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shane</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Folate and vitamin B12 metabolism: overview and interaction with riboflavin, vitamin B6, and polymorphisms</article-title>
                  <source>Food Nutr Bull</source>
                  <year>2008</year>
                  <volume>29</volume>
                  <issue>2</issue>
                  <fpage>S5</fpage>
                  <lpage>16</lpage>
                  <?supplied-pmid 18709878?>
                  <pub-id pub-id-type="pmid">18709878</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Plumptre</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Masih</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Ly</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Aufreiter</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sohn</surname>
                      <given-names>K-J</given-names>
                    </name>
                    <name>
                      <surname>Croxford</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>High concentrations of folate and unmetabolized folic acid in a cohort of pregnant Canadian women and umbilical cord blood</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2015</year>
                  <volume>102</volume>
                  <fpage>848</fpage>
                  <lpage>857</lpage>
                  <?supplied-pmid 26269367?>
                  <pub-id pub-id-type="pmid">26269367</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pfeiffer</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Sternberg</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Fazili</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Yetley</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Lacher</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Bailey</surname>
                      <given-names>RL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Unmetabolized folic acid is detected in nearly all serum samples from US children, adolescents, and adults</article-title>
                  <source>J Nutr</source>
                  <year>2015</year>
                  <volume>145</volume>
                  <issue>3</issue>
                  <fpage>520</fpage>
                  <lpage>531</lpage>
                  <?supplied-pmid 25733468?>
                  <pub-id pub-id-type="pmid">25733468</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Page</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Robichaud</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Arbuckle</surname>
                      <given-names>TE</given-names>
                    </name>
                    <name>
                      <surname>Fraser</surname>
                      <given-names>WD</given-names>
                    </name>
                    <name>
                      <surname>MacFarlane</surname>
                      <given-names>AJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Total folate and unmetabolized folic acid in the breast milk of a cross-section of Canadian women</article-title>
                  <source>Am J Clin Nutr</source>
                  <year>2017</year>
                  <volume>105</volume>
                  <issue>5</issue>
                  <fpage>1101</fpage>
                  <lpage>1109</lpage>
                  <?supplied-pmid 28298392?>
                  <pub-id pub-id-type="pmid">28298392</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Little</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Agostino</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Dickersin</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Emerson</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Farrar</surname>
                      <given-names>JT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The prevention and treatment of missing data in clinical trials</article-title>
                  <source>N Engl J Med</source>
                  <year>2012</year>
                  <volume>367</volume>
                  <issue>14</issue>
                  <fpage>1355</fpage>
                  <lpage>1360</lpage>
                  <?supplied-pmid 23034025?>
                  <pub-id pub-id-type="pmid">23034025</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
